Indefinite Delivery Contract 75D30122D14073
Award Date
7/1/22
Last Date to Order
6/30/23
Federal Agency
CDC Pittsburgh
Awardee
Pfizer Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc., a large pharmaceutical manufacturer. The $102,613,000 contract is for the delivery of 13 standard adult vaccines, including hepatitis, pneumococcal, tetanus, herpes zoster, measles/mumps/rubella, meningococcal, human papillomavirus, and varicella vaccines. Vaccines must have a minimum 12-month shelf life and be delivered within 15 business days...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. for the purchase of various adult vaccines. The $118.2 million contract, running from July 1, 2024 to June 30, 2025, covers a diverse array of vaccines including Hepatitis, HPV, Measles/Mumps/Rubella, Meningococcal, Mpox, Pneumococcal, and Varicella. The contract does not utilize any set-asides and allows for...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $1,517,947,500.00 and a period of performance from April 1, 2022 through March 31, 2023. It is a multiple award contract vehicle that will provide up to 23 standard pediatric vaccines to support CDC's Immunization Awardees and the Vaccines for...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor. The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to procure a variety of pediatric vaccines for the Vaccines for Children (VFC) program. The contract has a ceiling value of $1,914,795,500.00 and a period of performance from April 1, 2024 through March 31, 2025. The solicitation sought offers for 27 different pediatric vaccines including vaccines for diseases such as dengue, diphtheria,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. to purchase a variety of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.5 billion contract has a period of performance from April 1, 2023 to March 31, 2024. The contract will procure a minimum of 100 doses up to maximum quantities ranging from 100,000 to 13 million doses for 21...
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a leading global pharmaceutical corporation. The $425.5 million IDC, with a period of performance running from June 2023 to June 2024, is for the procurement of adult COVID-19 vaccines. As a major supplier of pharmaceutical products and vaccines to the U.S. federal government, Pfizer holds several significant Indefinite Delivery Vehicles (IDVs),...